Download
s00125-021-05498-0.pdf 1,36MB
WeightNameValue
1000 Titel
  • Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus
1000 Autor/in
  1. Kohlmorgen, Christina |
  2. Gerfer, Stephen |
  3. Feldmann, Kathrin |
  4. Twarock, Sören |
  5. Hartwig, Sonja |
  6. Lehr, Stefan |
  7. Klier, Meike |
  8. Krueger, Irena |
  9. Helten, Carolin |
  10. Keul, Petra |
  11. Kahl, Sabine |
  12. Polzin, Amin |
  13. Elvers, Margitta |
  14. Flögel, Ulrich |
  15. Kelm, Malte |
  16. Levkau, Bodo |
  17. Roden, Michael |
  18. Fischer, Jens W. |
  19. Grandoch, Maria |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-06-16
1000 Erschienen in
1000 Quellenangabe
  • 64(8):1834-1849
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00125-021-05498-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245397/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Aims/hypothesis!#!People with diabetes have an increased cardiovascular risk with an accelerated development of atherosclerosis and an elevated mortality rate after myocardial infarction. Therefore, cardioprotective effects of glucose-lowering therapies are of major importance for the pharmacotherapy of individuals with type 2 diabetes. For sodium-glucose cotransporter 2 inhibitors (SGLT2is), in addition to a reduction in blood glucose, beneficial effects on atherosclerosis, obesity, renal function and blood pressure have been observed. Recent results showed a reduced risk of worsening heart failure and cardiovascular deaths under dapagliflozin treatment irrespective of the diabetic state. However, the underlying mechanisms are yet unknown. Platelets are known drivers of atherosclerosis and atherothrombosis and disturbed platelet activation has also been suggested to occur in type 2 diabetes. Therefore, the present study investigates the impact of the SGLT2i dapagliflozin on the interplay between platelets and inflammation in atherogenesis.!##!Methods!#!Male, 8-week-old LDL-receptor-deficient (Ldlr!##!Results!#!Dapagliflozin treatment ameliorated atherosclerotic lesion development, reduced circulating platelet-leucocyte aggregates (glycoprotein [GP]Ib!##!Conclusions/interpretation!#!We demonstrate that dapagliflozin-mediated atheroprotection in mice is driven by elevated HDL-cholesterol and ameliorated thrombin-platelet-mediated inflammation without interfering with haemostasis. This glucose-independent mechanism likely contributes to dapagliflozin's beneficial cardiovascular risk profile.
1000 Sacherschließung
lokal Thrombin/metabolism [MeSH]
lokal Benzhydryl Compounds/therapeutic use [MeSH]
lokal Blood Platelets/metabolism [MeSH]
lokal HDL-cholesterol
lokal Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH]
lokal Heart failure
lokal Mice, Inbred C57BL [MeSH]
lokal P-Selectin/metabolism [MeSH]
lokal Flow Cytometry [MeSH]
lokal P-Selectin (CD62P)
lokal Atherosclerosis
lokal Diabetes Mellitus, Type 2/drug therapy [MeSH]
lokal Platelet Activation/drug effects [MeSH]
lokal Sodium–glucose cotransporter 2 (SGLT2) inhibitors
lokal Coronary Artery Disease/prevention
lokal Male [MeSH]
lokal Risk Reduction Behavior [MeSH]
lokal Healthy Volunteers [MeSH]
lokal Platelets
lokal Coronary Artery Disease/metabolism [MeSH]
lokal Cardiovascular Diseases/metabolism [MeSH]
lokal Female [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Dapagliflozin
lokal Middle Aged [MeSH]
lokal Platelet Count [MeSH]
lokal Cardiovascular Diseases/prevention
lokal Animals [MeSH]
lokal Cardiovascular
lokal Immunohistochemistry [MeSH]
lokal Article
lokal Glucosides/therapeutic use [MeSH]
lokal Cholesterol, HDL/blood [MeSH]
lokal Blood Glucose/metabolism [MeSH]
lokal Diabetes Mellitus, Type 2/metabolism [MeSH]
lokal Thrombin
lokal Blood Platelets/drug effects [MeSH]
lokal Real-Time Polymerase Chain Reaction [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S29obG1vcmdlbiwgQ2hyaXN0aW5h|https://orcid.org/0000-0002-6568-6766|https://frl.publisso.de/adhoc/uri/RmVsZG1hbm4sIEthdGhyaW4=|https://frl.publisso.de/adhoc/uri/VHdhcm9jaywgU8O2cmVu|https://orcid.org/0000-0002-5225-6804|https://orcid.org/0000-0003-3971-357X|https://frl.publisso.de/adhoc/uri/S2xpZXIsIE1laWtl|https://orcid.org/0000-0001-8451-4188|https://frl.publisso.de/adhoc/uri/SGVsdGVuLCBDYXJvbGlu|https://frl.publisso.de/adhoc/uri/S2V1bCwgUGV0cmE=|https://frl.publisso.de/adhoc/uri/S2FobCwgU2FiaW5l|https://frl.publisso.de/adhoc/uri/UG9semluLCBBbWlu|https://frl.publisso.de/adhoc/uri/RWx2ZXJzLCBNYXJnaXR0YQ==|https://frl.publisso.de/adhoc/uri/RmzDtmdlbCwgVWxyaWNo|https://orcid.org/0000-0003-0060-1052|https://orcid.org/0000-0002-0005-125X|https://orcid.org/0000-0001-8200-6382|https://frl.publisso.de/adhoc/uri/RmlzY2hlciwgSmVucyBXLg==|https://orcid.org/0000-0002-4382-1947
1000 Hinweis
  • DeepGreen-ID: 382c98869e504cc2b893120f4f5d0904 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451904.rdf
1000 Erstellt am 2023-05-12T10:41:07.831+0200
1000 Erstellt von 322
1000 beschreibt frl:6451904
1000 Zuletzt bearbeitet 2023-10-24T07:09:09.485+0200
1000 Objekt bearb. Tue Oct 24 07:09:09 CEST 2023
1000 Vgl. frl:6451904
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451904 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source